(Q51097389)

English

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

scientific article published in June 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. (English)

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles M. Beasley

3

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

author name string

G D Tollefson

1

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

T M Sanger

2

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

P V Tran

4

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

language of work or name

0 references

publication date

1 June 1998

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

Biological Psychiatry

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

43

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

803-810

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

11

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis.

2 references

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Schizophrenics kill themselves too: a review of risk factors for suicide

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Schizophrenia as dopamine-deficiency disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Measurement of mood and affect in schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The Causality of Depression in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The significance of depression in the prediction of relapse in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

'Revealed' Depression and Drug Treatment for Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The clinical course of depressive symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

The Mechanism of Action of Novel Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depressive symptoms in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Negative and positive symptoms in schizophrenia and depression: a followup

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

'Akinetic Depression' in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900093-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-3223(98)00093-6

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

release_lzsmuv2y2rabdh4sfcvgnehzlu

1 reference

https://api.fatcat.wiki/v0/release/lzsmuv2y2rabdh4sfcvgnehzlu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 March 2018

http://europepmc.org/abstract/MED/9611669

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51097389&oldid=1842875034"